Abstract
Wastewater surveillance for infectious agents has proved useful in identifying circulation of viruses within populations. We investigated the presence and concentration of human immunodeficiency virus (HIV)-1 total nucleic acids (including both viral RNA and proviral DNA) in wastewater solids. We retrospectively measured HIV-1 nucleic-acids in two samples per week for 26 months at two wastewater treatment plants serving populations with different prevalences of HIV infections in San Francisco and Santa Clara County, California, USA. We detected HIV nucleic-acids in a majority of samples with concentrations ranging from non-detect to 3.9×105 cp/g (N=459 samples total). Concentrations of HIV-1 were significantly higher in samples from the wastewater treatment plant serving a population with a higher prevalence of people living with HIV than in the plant serving a population with lower prevalence. The HIV-1 nucleic-acids amplified were primarily DNA and thus represented proviral DNA shedding into wastewater. Additionally, we found that HIV-1 nucleic-acid concentrations in wastewater solids were orders of magnitude higher than those in liquid wastewater indicating that the HIV-1 target preferentially sorbs to solids. Whether concentrations of HIV-1 in wastewater solids can be used to identify numbers of incident cases remains unknown. Additional work on HIV-1 shedding from individuals with viremia and people living with HIV is needed to translate wastewater measurements to quantitative information on infections.
Competing Interest Statement
Dorothea Duong, Bridgette Shelden and Bradley White are employees of Verily Life Sciences, LLC
Funding Statement
This study was funded in part by National Institute of Health (R21-AI179550) and the Sergey Brin Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at https://www.cdc.gov/hiv/library/reports/index.html, https://publichealth.sccgov.org/sites/g/files/exjcpb916/files/documents/STIHIV_AnnualReport_2022.pdf, https://publichealth.sccgov.org/sites/g/files/exjcpb916/files/documents/STIHIV_AnnualReport_2021.pdf, https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2022-Orange.pdf
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at the Stanford Digital Repository.
